Filing Details
- Accession Number:
- 0001415889-17-000282
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-02-16 19:06:35
- Reporting Period:
- 2017-02-14
- Filing Date:
- 2017-02-16
- Accepted Time:
- 2017-02-16 19:06:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1454276 | O Terrence Moore | 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 | Evp, Chief Commercial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-02-14 | 87,128 | $19.61 | 90,759 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-14 | 89,088 | $39.69 | 1,671 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2017-02-15 | 1,700 | $19.61 | 3,371 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-15 | 1,700 | $39.65 | 1,671 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2017-02-16 | 17,421 | $19.61 | 19,092 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-02-16 | 19,687 | $27.20 | 38,779 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-02-16 | 29,644 | $34.45 | 68,423 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-16 | 66,752 | $39.88 | 1,671 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2017-02-14 | 12,747 | $0.00 | 12,747 | $19.61 |
| Common Stock | Stock Option (right to buy) | Disposition | 2017-02-14 | 74,381 | $0.00 | 74,381 | $19.61 |
| Common Stock | Stock Option (right to buy) | Disposition | 2017-02-15 | 1,700 | $0.00 | 1,700 | $19.61 |
| Common Stock | Stock Option (right to buy) | Disposition | 2017-02-16 | 17,421 | $0.00 | 17,421 | $19.61 |
| Common Stock | Stock Option (right to buy) | Disposition | 2017-02-16 | 19,687 | $0.00 | 19,687 | $27.20 |
| Common Stock | Stock Option (right to buy) | Disposition | 2017-02-16 | 29,644 | $0.00 | 29,644 | $34.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,649 | 2023-08-18 | No | 4 | M | Direct | |
| 55,223 | 2023-08-18 | No | 4 | M | Direct | |
| 53,523 | 2023-08-18 | No | 4 | M | Direct | |
| 36,102 | 2023-08-18 | No | 4 | M | Direct | |
| 13,125 | 2024-03-06 | No | 4 | M | Direct | |
| 90,356 | 2025-03-19 | No | 4 | M | Direct |
Footnotes
- Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
- 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
- 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
Billionaire Hedge Funds
